Measurement of the incretin hormones: Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide

Journal of Diabetes and its Complications

Volumn 29, Issue 3, 2015, Pages 445-450

  Kuhre, Rune Ehrenreich ^b   Wewer Albrechtsen, Nicolai Jacob ^b   Hartmann, Bolette ^b   Deacon, Carolyn F ^b   Holst, Jens Juul ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ELISA; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Incretin hormones; RIA

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ARTICLE; GLUCOSE HOMEOSTASIS; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; CHEMISTRY; ENDOCRINE SYSTEM EXAMINATION; IMMUNOLOGICAL PROCEDURES; METABOLISM; STANDARDS;

DIAGNOSTIC TECHNIQUES, ENDOCRINE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IMMUNOLOGIC TESTS; INCRETINS;

EID: 84925358910     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.12.006     Document Type: Review

References (42)

1. M.J. Bak Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans European Journal of Endocrinology/European Federation of Endocrine Societies 170 4 2014 529 538
2. M.J. Bak Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies Diabetes, Obesity & Metabolism 16 11 2014 1155 1164
3. F.G. Baldissera, and J.J. Holst Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs Diabetologia 29 7 1986 462 467
4. S.A. Berson Insulin-I131 metabolism in human subjects: Demonstration of insulin binding globulin in the circulation of insulin treated subjects The Journal of Clinical Investigation 35 2 1956 170 190
5. D. Bousquet-Moore Reversal of physiological deficits caused by diminished levels of peptidylglycine α-amidating monooxygenase by dietary copper Endocrinology 150 4 2009 1739 1747
6. A.M. Buchan Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man Histochemistry 56 1 1978 37 44
7. J. Cox, and M. Mann MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nature Biotechnology 26 12 2008 1367 1372
8. W. Creutzfeldt The incretin concept today Diabetologia 16 2 1979 75 85
9. C.F. Deacon, and B. Ahren Physiology of incretins in health and disease The Review of Diabetic Studies: RDS 8 3 2011 293 306
10. C.F. Deacon, and J.J. Holst Immunoassays for the incretin hormones GIP and GLP-1 Best Practice & Research. Clinical Endocrinology & Metabolism 23 4 2009 425 432
11. C.F. Deacon Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig The American Journal of Physiology 271 3 Pt. 1 1996 E458 E464
12. C.F. Deacon, M.A. Nauck, J. Meier, K. Hücking, and J.J. Holst Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide The Journal of Clinical Endocrinology and Metabolism 85 10 2000 3575 3581
13. H. Elrick Plasma insulin response to oral and intravenous glucose administration The Journal of Clinical Endocrinology and Metabolism 24 10 1964 1076 1082
14. E. Engvall, and P. Perlmann Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G Immunochemistry 8 9 1971 871 874
15. G. Gu Glucagon-like peptide-1 in the rat brain: Distribution of expression and functional implication The Journal of Comparative Neurology 521 10 2013 2235 2261
16. C.M. Hammers, and J.R. Stanley Antibody phage display: Technique and applications The Journal of Investigative Dermatology 134 2 2014 e17 (1-5)
17. L. Hansen Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 140 11 1999 5356 5363
18. K.R. Hjollund, C.F. Deacon, and J.J. Holst Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs, in Diabetologia 2011 Springer-Verlag 2206 2208
19. J.J. Holst The physiology of glucagon-like peptide 1 Physiological Reviews 87 4 2007 1409 1439
20. J.J. Holst Circulating glucagon after total pancreatectomy in man Diabetologia 25 5 1983 396 399
21. J.J. Holst Proglucagon processing in porcine and human pancreas Journal of Biological Chemistry 269 29 1994 18827 18833
22. J.J. Holst Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Diabetes Care 34 Suppl 2 2011 S251 S257
23. K. Hupe-Sodmann Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides Regulatory Peptides 58 3 1995 149 156
24. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 8 1995 3585 3596
25. T. Krarup Immunoreactive gastric inhibitory polypeptide Endocrine Reviews 9 1 1988 122 134
26. T. Krarup, and J.J. Holst The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera Regulatory Peptides 9 1-2 1984 35 46
27. R.E. Kuhre GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines Peptides 55 2014 52 57
28. N.A. Kulak Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells Nature Methods 11 3 2014 319 324
29. P.J. Larsen, and J.J. Holst Glucagon-related peptide 1 (GLP-1): Hormone and neurotransmitter Regulatory Peptides 128 2 2005 97 107
30. A. Michalski Ultra high resolution linear ion trap Orbitrap Mass Spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes Molecular & Cellular Proteomics: MCP 11 3 2012
31. K. Mortensen GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine Regulatory Peptides 114 2-3 2003 189 196
32. M.A. Nauck Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses The Journal of Clinical Endocrinology and Metabolism 63 2 1986 492 498
33. M. Nauck Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 1 1986 46 52
34. M.A. Nauck Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down? Diabetologia 54 1 2011 10 18
35. C. Orskov Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans Diabetes 43 4 1994 535 539
36. M.J. Perley, and D.M. Kipnis Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects The Journal of Clinical Investigation 46 12 1967 1954 1962
37. A. Plamboeck Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig Diabetologia 48 9 2005 1882 1890
38. R. Ugleholdt Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor The Journal of Biological Chemistry 281 16 2006 11050 11057
39. T. Vilsboll Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects The Journal of Clinical Endocrinology and Metabolism 88 1 2003 220 224
40. N.J. Wewer Albrechtsen Targeting the intestinal L-cell for obesity and type 2 diabetes treatment Expert Review of Endocrinology & Metabolism 9 01 2014 61 72
41. N. Wewer Albrechtsen Hyperglucagonaemia analysed by glucagon sandwich ELISA: Nonspecific interference or truly elevated levels? Diabetologia 2014 1 8
42. G. Winter Making antibodies by phage display technology Annual Review of Immunology 12 1 1994 433 455